remdesivir

Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease. Gilead CEO On Remdesivir: Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir received an emergency use authorization designation in...

Gilead Sciences, Inc (NASDAQ: GILD) announced Monday it was seeking complete Food and Drug Administration approval for its drug Remdesivir, which is being used in the treatment of COVID-19. What Happened The drugmaker said it has filed a New Drug Application with the FDA on the basis of...

Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. (NASDAQ: GILD) announced a deal Friday for GIlead's remdesivir, which has been accorded emergency use authorization by the FDA for treating COVID-19. The Pfizer-Gilead Partnership: Pfizer said it has entered a...

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...

Many investors are working under the assumption that a safe vaccine against the coronavirus will allow society to return to how it was pre-pandemic. Investors may be missing part of the story, including how the vaccines work, former FDA Commissioner Dr. Scott Gottlieb said on CNBC's "...

The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse.  Biotechs To Outperform In Q2? The biotech sector is not only the likely source of the solution to the pandemicm but is also fairly...

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy. Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities. Mixed Results...

Gilead Sciences, Inc. (NASDAQ: GILD) shares are seeing some upward momentum following the biopharma's announcement of additional data on its COVID-19 treatment candidate remdesivir. What Happened: Gilead said a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world...

Gilead Sciences, Inc. (NASDAQ: GILD) announced pricing Monday for its antiviral remdesivir, which has been granted  emergency use authorization by the FDA for treating COVID-19. The Price Of Remdesivir: The biopharma has set a price of $390 per vial for the governments of developed...

The United States Food and Drug Administration on Monday withdrew the emergency use authorization it granted for hydroxychloroquine and chloroquine sulfates against the COVID-19 coronavirus. The federal agency had granted the EUA for the antimalarial drugs in late March based on preliminary studies...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) traded lower by 4% on Thursday amid broad market weakness following a spike in U.S. coronavirus cases. Gilead’s remdesivir is one of the most advanced potential treatments for COVID-19, but several options traders made large bets on Thursday that...

The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS), according to Leerink. The Gilead Sciences Analyst Geoffrey...

COVID-19 coronavirus made us realize that health should always be our top priority. Here are some companies working to make the world a better place after the pandemic.  AbbVie Inc – Botox To The Rescue With unappreciated potential, the stock of this big drugmaker has stellar...

Gilead Sciences, Inc. (NASDAQ: GILD) shares have come under selling pressure after the company released results Monday from a Phase 3 study of its COVID-19 treatment candidate remdesivir. Gilead's Mixed Remdesivir Data The company announced topline results from the Phase 3 SIMPLE study in...

The U.K. approved the use Tuesday of Gilead Sciences Inc's (NASDAQ: GILD) remdesivir for some patients with COVID-19.  The drug is to be made available on the NHS for some patients. U.K. Health Minister Matt Hancock says the antiviral drug is probably the biggest step forward...